Compare COLL & ASTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLL | ASTH |
|---|---|---|
| Founded | 2002 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2015 | 2015 |
| Metric | COLL | ASTH |
|---|---|---|
| Price | $34.50 | $24.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $50.83 | $35.33 |
| AVG Volume (30 Days) | 400.6K | ★ 500.6K |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.73 | 0.46 |
| Revenue | ★ $780,567,000.00 | $519,907,752.00 |
| Revenue This Year | $6.07 | $26.88 |
| Revenue Next Year | N/A | $10.78 |
| P/E Ratio | ★ $20.21 | $50.54 |
| Revenue Growth | 23.62 | ★ 45.90 |
| 52 Week Low | $23.23 | $18.08 |
| 52 Week High | $50.79 | $34.80 |
| Indicator | COLL | ASTH |
|---|---|---|
| Relative Strength Index (RSI) | 16.51 | 54.88 |
| Support Level | $34.30 | $20.98 |
| Resistance Level | $36.20 | $28.02 |
| Average True Range (ATR) | 1.59 | 1.47 |
| MACD | -0.70 | 0.28 |
| Stochastic Oscillator | 2.18 | 67.40 |
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.